Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.
Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP1 operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback